Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Candel Therapeutics (CADL) Shares Outstanding (Weighted Average) (2020 - 2025)

Candel Therapeutics' Shares Outstanding (Weighted Average) history spans 4 years, with the latest figure at $28.9 million for Q4 2023.

  • On a quarterly basis, Shares Outstanding (Weighted Average) changed 0.39% to $28.9 million in Q4 2023 year-over-year; TTM through Dec 2023 was $28.9 million, a 0.39% change, with the full-year FY2023 number at $28.9 million, changed 0.39% from a year prior.
  • Shares Outstanding (Weighted Average) hit $28.9 million in Q4 2023 for Candel Therapeutics, roughly flat from $28.9 million in the prior quarter.
  • Over the last five years, Shares Outstanding (Weighted Average) for CADL hit a ceiling of $28.9 million in Q4 2023 and a floor of $11.6 million in Q2 2020.
  • Historically, Shares Outstanding (Weighted Average) has averaged $22.1 million across 4 years, with a median of $28.7 million in 2022.
  • Biggest five-year swings in Shares Outstanding (Weighted Average): soared 146.32% in 2022 and later increased 0.39% in 2023.
  • Tracing CADL's Shares Outstanding (Weighted Average) over 4 years: stood at $11.6 million in 2020, then surged by 62.49% to $18.9 million in 2021, then skyrocketed by 52.72% to $28.8 million in 2022, then increased by 0.39% to $28.9 million in 2023.
  • Business Quant data shows Shares Outstanding (Weighted Average) for CADL at $28.9 million in Q4 2023, $28.9 million in Q3 2023, and $28.9 million in Q2 2023.